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ABSTRACT 
Carnitine palmitoyltransferase I (CPT-I) and II (CPT-II) enzymes are components of the 
carnitine palmitoyltransferase shuttle system which allows entry of long-chain fatty 
acids into the mitochondrial matrix for subsequent oxidation. This system is tightly 
regulated by malonyl-CoA levels since this metabolite is a strong reversible inhibitor of 
the CPT-I enzyme. There are two distinct CPT-I isotypes (CPT-Iα and CPT-Iβ), that 
exhibit different sensitivity to malonyl-CoA inhibition. Because of its ability to inhibit 
fatty acid synthase (FAS), C75 is able to increase malonyl-CoA intracellular levels. 
Paradoxically it also activates long-chain fatty acid oxidation. To identify the exact 
target of C75 within the CPT system, we expressed individually the different 
components of the system in the yeast Pichia pastoris. We show here that C75 acts on 
recombinant CPT-Iα, but also on the other CPT-I isotype (CPT-Iβ) and the malonyl-
CoA insensitive component of the CPT system, CPT-II.  
 
 INTRODUCTION 
C75 was initially synthesized as a chemically stable inhibitor of mammalian fatty acid 
synthase (FAS) [1]. FAS catalyses long-chain fatty acid synthesis through the 
condensation of acetyl-CoA and malonyl-CoA. Malonyl-CoA is a potent inhibitor of 
carnitine palmitoyltransferase I (CPT-I), a component of the CPT system, which 
controls the entry of long-chain fatty acids into the mitochondria [2]. Thus, it could be 
expected that FAS inhibition would increase malonyl-CoA levels that in turn would 
down regulate fatty acid β-oxidation through CPT-I inhibition. However, it has been 
shown that C75 increases fatty acid oxidation in diet induced obesity [3]. 
C75 exerts its actions through several mechanisms. In the hypothalamus, C75 causes 
suppression of food intake by preventing fasting-induced up-regulation of the 
orexigenic neuropeptides NPY and AgRP and down-regulation of the anorexigenic 
neuropeptides POMC and CART [4-6]. In the peripherical tissues C75 acts on two key 
steps of lipid metabolism: FAS and CPT. As a result of FAS inhibition, lipid synthesis 
is down regulated and malonyl-CoA level increase. However, In vitro studies using 
primary rat hepatocytes and cell line models showed that C75-mediated increase of 
malonyl-CoA concentration does not cause inhibition of fatty acid oxidation as 
predicted but on the contrary revealed that C75 is able to activate the CPT system in the 
presence of inhibitory concentrations of malonyl-CoA [3]. Altogether these mechanisms 
of action are responsible for the loose of appetite, the reduction of adipose mass [4] and 
fatty liver [5] observed after C75 treatment. 
The CPT system is involved in the translocation of long chain acyl-CoA across the 
mitochondria membrane, and is composed of three enzymes: CPT-I, 
carnitine/acylcarnitine translocase, and CPT-II. The CPT-I activity catalyzes the initial 
step of the process by converting the acyl-CoA into acylcarnitine esters in the presence 
of L-carnitine. The carnitine/acylcarnitine translocase promotes the transit of 
acylcarnitine esters across the mitochondrial inner membrane and, finally, the CPT-II 
enzyme regenerates the long-chain acyl-CoA from the acylcarnitine esters, hence 
providing substrates for β-oxidation. Because CPT-I catalyzes the first rate-limiting step 
in the carnitine shuttle system and because of its tightly regulation by its physiological 
inhibitor malonyl-CoA, it is considered the most critical step in controlling fatty acid 
flux through the β-oxidation pathway [2]. However, at the transcriptional level CPT-I is 
not the sole enzyme regulated since it has been showed the CPT-II is regulated by 
starvation [7] and PPAR (Peroxisome Proliferator Activated Receptor) [8]. 
Two main isotypes of CPT-I exist: CPT-Iα and CPT-Iβ. CPT-Iα is highly expressed in 
liver and in a wide variety of tissues. CPT-Iβ is only expressed in muscle, adipose 
tissue, heart, and testis. Both enzymes differ markedly in their kinetics characteristics, 
namely the Km for carnitine and the sensibility to malonyl-CoA inhibition. CPT-Iα 
shows a lower Km for carnitine and a low sensitivity to malonyl-CoA inhibition (higher 
IC50), while CPT-Iβ has a high Km for carnitine and a higher sensitivity to malonyl-CoA 
(lower IC50) [2]. These kinetic characteristics are preserved by the recombinants 
enzymes when expressed in Pichia pastoris [9-11]. The differences between both 
isotypes are not universally conserved since it has been recently showed that porcine 
CPT-I isotypes behave as natural chimera of CPT-I isotypes: pig CPT-Iα has a high 
affinity for carnitine but also high sensibility to malonyl-CoA inhibition [12, 13] while 
pig CPT-Iβ has a low affinity for carnitine and a low sensibility to malonyl-CoA 
inhibition [14]. 
Thupari et al. [3] concluded that C75 stimulates CPT-I activity. However, considering 
the experimental approach used, the action of C75 on the malonyl-CoA insensitive 
component of the CPT system can not be discarded, since under the assay conditions 
both CPT-I and CPT-II catalyze the same reaction, the formation of palmitoylcarnitine 
from carnitine and palmitoyl-CoA [11, 15]. 
Moreover, Thupari et al. [3] worked with different cellular systems - primary 
hepatocytes, NCF-7 human breast cells cancer line and with mouse 3T3-L1 adipocytes- 
that all express the α isotype of CPT-I (mouse 3T3-L1 adipocytes, unlike other 
adipocytes express the α isotype [16]). Hence, they could not investigate the effects of 
C75 on CPT-Iβ, the isotype expressed in adipose tissue, one of the tissues of major 
interest with regard to β-oxidation. 
To distinguish between CPT-I and CPT-II activities, and also to study the β isotype, we 
expressed individually the different CPT enzymes in the yeast Pichia pastoris, devoid 
of endogenous CPT activity, and analysed the effect of C75. This study was 
complemented with experimental setups in mammalian cell lines that allowed 
distinction between CPT-I and CPT-II activities. 
 
MATERIALS AND METHODS 
Construction of Plasmids for CPT Expression in P. pastoris – All expression plasmids 
used for the expression of rat CPT-Iα [11], pig CPT-Iα [12], human CPT-Iβ [9], and 
CPT-II [11], were constructed in a similar way in which an EcoRI site was introduced 
immediately upstream of the ATG start codon to enable cloning into the unique EcoRI 
site located 3’ of the glyceraldehid-3-phosphate dehydrogenase gene promoter (GAPp) 
in pHWO10 plasmid [11, 17] The constructs were linearized in the GAP gene promoter 
by digestion with AvrII and integrated into the GAPp locus of P. pastoris GS115 by 
electroporation [18]. Histidine prototrophic transformants were selected on YND plates 
and grown on YND medium. Mitochondria were isolated by disrupting the yeast cells 
with glass beads as previously described [11, 19]. 
Carnitine palmitoyltransferase assay in P. pastors mitochondria – CPT activity was 
assayed by the forward exchange method using L-[3H] carnitine as previously described 
[11]. In a total volume of 0.5 mL, the standard enzyme assay mixture contained 0.2 mM 
(for pig CPT-Iα, rat CPT-Iα, and rat CPT-II) or 1 mM (for human CPT-Iβ) of L-
[3H]carnitine (~5 000 dpm/nmol) 80 µM palmitoyl-CoA, 20 mM HEPES (pH 7.0), 1% 
fatty acid-free albumin, and 40-75 mM KCl, with or without 10 µM malonyl-CoA 
and/or 200 µM C75 (Alexis Biochemicals) as indicated. Reactions were initiated by 
addition of 0.1 mg of isolated intact yeast mitochondria. The reaction was linear up to 4 
min, and all incubations were done at 30 ºC for 3 min. with or without malonyl-CoA 
and/or C75, as indicated. Reactions were stopped by addition of 6% perchloric acid and 
were then centrifuged at 2000 rpm for 7 min. The resulting pellet was suspended in 
water, and the product [3H] palmitoylcarnitine was extracted with butanol at low pH. 
After centrifugation at 2000 rpm for 2 min, an aliquot of the butanol phase was 
transferred to a vial for radioactive counting 
Carnitine palmitoyltransferase assay in mammalian cell lines - Cells were grown to 
confluence and collected in PBS (Phosphate buffer saline). Cells were collected by 
centrifugation and resuspended in buffer A (KCl 150mM, Tris HCl 5mM pH 7.2) and 
broken with 10 cycles of glass homogenizer (tight fitting pestle). Mitochondria were 
collected by centrifugation (16000g, 5 min. 4ºC) and resuspended in buffer A. At this 
step mitochondria could either be used for total CPT activity assay or processed for 
CPT-II activity determination by frozen and thawed, and then incubated for 30 minutes 
at 4°C in presence of 1% octylglucoside. This treatment inhibits CPT-I activity [20] and 
hence, once the membrane debris are removed by centrifugation (16000g, 2 min at 4ºC), 
allow direct measurement of CPT-II activity. 
For both total CPT and CPT-II assay, 100µg of protein were used for the enzymatic 
assay. The CPT assay was performed using the same protocol as for P. pastoris 
mitochondria. To ensure that the CPT-II assay worked correctly an alternative protocol 
was developed: before harvest, cells were treated for 2 hours with etomoxir or vehicle 
(DMSO) in order to irreversibly inhibit CPT-I activity. Cells were then collected and 
processed as for total CPT or CPTII assay. Etomoxir inhibition of CPT-I activity gave 
the same results than measured by octylglucoside treatment of mitochondrial 
preparations, which validated the assay (results not shown). 
 
RESULTS AND DISCUSSION. 
To study the effect of C75 on the CPT system, recombinant rat CPT-Iα and human 
CPT-Iβ were expressed in Pichia pastoris. As shown in Figure 1A and 1B, C75 
activates rat CPT-Iα (23.18%) and human CPT-Iβ (33.02%) recombinant enzymes. The 
stimulatory effect of C75 is maintained when the CPT-I activity is measured in presence 
of 10 µM malonyl-CoA: rat CPT-Iα is activated 23.35% and human CPT-Iβ 44.44%. 
We also expressed pig CPT-Iα, since this enzyme is a natural chimera which a km for 
carnitine characteristic of the α isotype but a sensitivity to malonyl-CoA inhibition 
characteristic of the β isotype [12]. Figure 1C shows that C75 activates pig CPT-Iα in 
the absence (23.88%) or in the presence of malonyl-CoA 10 µM (28.88%).  
The increase in the activity of CPT-Iα by C75, even in the presence of inhibitory 
concentration of malonyl-CoA, has been used as an argument to explain the C75 
paradox, in which this compound is able to simultaneously stimulate fatty acid β-
oxidation and malonyl-CoA accumulation [3]. However, the total activity of CPT-I, in 
the presence of C75 and malonyl-CoA, still remains lower than the activity in the 
absence of malonyl-CoA (Figure 1), questioning such explanation in physiologic 
conditions. 
C75 stimulation of CPT-I activity was lower than reported in primary culture cells [3], 
and appears unrelated with the different sensibility to malonyl-CoA of the recombinant 
enzymes. Therefore, we studied the effect the C75 on CPT-II activity. Figure 2A shows 
that C75 stimulates recombinant CPT-II activity (30.73%) in a similar way than the 
CPT-I activity. To confirm this result we determined C75 effect on endogenous CPT-II 
activity from CHO and Cos-7 cell lines. Since CPT-II or CPT-I in vitro determinations 
are based in the same assay [11, 15], we took advantage of octylgucoside, a detergent 
that promotes specific inactivation of the CPT-I activity [20], to exclusively assay CPT-
II activity. Figure 2B shows that C75 stimulates the activity of CPT-II enzyme in CHO 
(90.29%) and Cos-7 (123.91%) cell lines. 
All together these results indicate that C75 acts directly on the CPT shuttle system, 
since C75 activation extends to different isotypes of CPT-I and to the CPT-II enzyme. 
Therefore, this result could explain the activation of the fatty acid oxidation by C75 in 
different tissues, independently of the CPT-I isotype expressed.  
CPTII deficiency is among the most common inborn errors of mitochondrial fatty acid 
β-oxidation. Recently, in CPT-II-deficient cultured human skin fibroblasts, it has been 
observed that up-regulation of CPTII expression mediated by bezafibrate improves fatty 
acid oxidation rate [21]. This data is consistent with the presence of a PPRE in the 5'-
flanking region of the human CPTII gene [8] and therefore validates the CPTII as a 
potential pharmacological target. We show now that CPTII gene can also be regulated at 
the post-transcriptional level by C75. 
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FIGURE LEGENDS 
Figure 1. C75 activates recombinant CPT-Iα, and CPT-Iβ. Pichia pastoris were 
transformed with the plasmids encoding for the rat CPT-Iα (A), human CPT-Iβ (B), 
or pig CPT-Iα (C). Mitochondria isolated from these strains were assayed for CPT 
activity in the presence of DMSO (vehicle), 200 µM of C75, or 10 µM of malonyl-
CoA, as described in the Material and Methods section. Results are an average of at 
least three separate experiments with at least two independent mitochondrial 
preparations. * (p<0.005). ** (p<0.05) 
Figure 2. C75 activates CPT-II. (A) Pichia pastoris were transformed with the 
plasmid encoding for the rat CPT-IΙ. Mitochondria isolated from these strains were 
assayed for CPT activity in the presence of DMSO (vehicle) or 200 µM of C75, as 
described in the Material and Methods section. Results are an average of three 
separate experiments with at least two independent mitochondrial preparations. (B) 
Cos-7 or CHO mitochondria were treated with octylglucoside to inactivated CPT-I, 
as described in the Material and Methods section. Mitochondria were subsequently 
assayed for CPTII activity in the presence of DMSO (vehicle) or 200 µM of C75. 
Results are an average of at least three separate experiments with at least two 
independent mitochondrial preparations. * (p<0.005). 
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